Related Experiment Video

Updated: Aug 12, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib

Holger Rumpold1, Anna M Wolf, Kurt Gruenewald

  • 1Laboratory of Tumorbiology and Angiogenesis, Division of Hematology and Oncology, Medical University of Innsbruck, Austria.

Experimental Hematology
|June 21, 2005
PubMed
Abstract

Insights

This study developed a nonviral gene therapy to reduce P-glycoprotein (PgP) in leukemia cells. This approach reversed drug resistance, offering a potential new strategy for treating hematologic malignancies.

Area of Science:

  • Hematology
  • Molecular Biology
  • Gene Therapy

Background:

  • Drug resistance in hematologic malignancies like leukemia and lymphoma leads to treatment failure.
  • Overexpression of the multidrug-resistance gene (MDR-1) and its product P-glycoprotein (PgP) is a key mechanism of this resistance.

Purpose of the Study:

  • To develop a nonviral vector system for stable knockdown of PgP.
  • To evaluate the efficacy of this system in reversing drug resistance in chronic myeloid leukemia (CML) cell lines.

Main Methods:

  • Construction of a nonviral, transposon-based vector system.
  • Stable knockdown of PgP in imatinib- and doxorubicin-resistant CML cell lines.
  • Assessment of PgP expression levels and cellular drug efflux.

Main Results:

  • Complete knockdown of PgP expression was achieved within 72 hours and persisted for months.
  • Cellular efflux of PgP substrates (rhodamine, doxorubicin) was abolished.
  • Vector-treated cells regained sensitivity to imatinib and doxorubicin, leading to cell death.

Conclusions:

  • Nonviral, transposon-based knockdown of PgP durably reverses PgP-mediated resistance.
  • This strategy shows promise for overcoming imatinib and anthracycline resistance in CML.
  • This approach could be a valuable tool for treating drug-resistant hematologic malignancies.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Inducible and Reversible Dominant-negative (DN) Protein Inhibition08:35

Inducible and Reversible Dominant-negative (DN) Protein Inhibition

Published on: January 7, 2019

Related Concept Videos

In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
piRNA - Piwi-interacting RNAs02:57

piRNA - Piwi-interacting RNAs

PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...